Potentiation of tumour promotion by topical application of argemone oil/isolated sanguinarine alkaloid in a model of mouse skin carcinogenesis

Several incidences of adverse effects on human health have been reported in many countries, due to consumption of edible oil adulterated with argemone oil (AO). The clinical manifestation of the disease is commonly referred to as epidemic dropsy. Our prior studies have shown that AO and isolated sanguinarine alkaloid (SANG) possess genotoxic and tumour initiating activity. In this study, the effect of AO/SANG was investigated on the development of tumour formation in mice using 7,12-dimethylbenz (a) anthracene (DMBA) initiated followed by tetradecanoyl phorbol acetate (TPA)-promoted skin tumour protocol. Single application of AO (300 mu l) or SANG (4.5 mu mol) when used during initiation phase in DMBA/TPA group did not reveal substantial difference in tumourigenic response. However, twice weekly application of AO (100 mu l) or SANG (1.5 mu mol) during promotion phase (25 weeks) resulted in enhanced tumourigenic response by >= 30% in DMBA/TPA treated group along with significant decrease in dermal tyrosinase (45-49%), histidase (30-32%), superoxide dismutase (53-56%), catalase (41%). GSH reductase (37-40%) and GSH-peroxidase activity (29-33%) compared to control. Furthermore, significant decrease of epidermal GSH (64-66%) content and enhanced formation of lipid peroxides (96-121%) was noticed following AO or SANG treatment during promotion phase to DMBA/TPA induced animals indicating the modified pro-oxidant status in skin. Although dermal biochemical parameters were also altered by AO or SANG when used during initiation phase in DMBA/TPA treated animals, nonetheless, the response in these parameters were relatively more when AO or SANG were used during promotion phase in DMBA/TPA treated animals. These results clearly suggest that AO and SANG have the ability to enhance the tumourigenic response, which may have relevance to its carcinogenic potential. (C) 2010 Elsevier Ireland Ltd. All rights reserved.